We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+19.53%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$368M
AUM Growth
+$56.7M
Cap. Flow
+$6.48M
Cap. Flow %
1.76%
Top 10 Hldgs %
98.88%
Holding
13
New
–
Increased
6
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.2M
2
ALKS icon
Alkermes
ALKS
+$6.45M
3
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$4.53M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$3.29M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$3.25M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$8.8M
2
UTHR icon
United Therapeutics
UTHR
+$7.55M
3
ANAB icon
AnaptysBio
ANAB
+$4.74M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.04M
5
MCK icon
McKesson
MCK
+$313K

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$57.2M 15.56%
472,548
-67,098
-12% -$7.55M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$55.4M 15.06%
493,170
+31,032
+7% +$3.29M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$49.7M 13.52%
79,691
-7,126
-8% -$4.04M
BIIB icon
4
Biogen
BIIB
$30B
$40.5M 11.02%
151,420
+40,649
+37% +$12.2M
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$366M
$38.3M 10.42%
763,103
+62,785
+9% +$3.25M
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$34.7M 9.43%
521,507
+34,232
+7% +$2.3M
MCK icon
7
McKesson
MCK
$100B
$33.2M 9.02%
216,142
-2,164
-1% -$313K
ALKS icon
8
Alkermes
ALKS
$8.22B
$30.4M 8.26%
1,564,665
+397,034
+34% +$6.45M
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$18.6M 5.06%
195,052
+60,793
+45% +$4.53M
IVC
10
DELISTED
Invacare Corporation
IVC
$5.58M 1.52%
876,421
-10,825
-1% -$72.4K
ANAB icon
11
AnaptysBio
ANAB
$1.58B
$4.13M 1.12%
184,846
-259,031
-58% -$4.74M
GILD icon
12
Gilead Sciences
GILD
$162B
– –
-117,755
Closed -$8.8M
CHNG
13
DELISTED
Change Healthcare Inc. Common Stock
CHNG
– –
-3,639
Closed -$36K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Krensavage Asset Management held 13 positions worth $368M, up 18% from $311M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Krensavage Asset Management's Q2 2020 filing shows 6 increased, 5 reduced and 2 closed positions. The largest sale was Gilead Sciences, an estimated $8.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Technology.

  • Krensavage Asset Management added most to Biogen in Q2 2020, an estimated $12.2M increase.
  • Krensavage Asset Management's biggest Q2 2020 reduction was United Therapeutics, cutting an estimated $7.55M.
  • Krensavage Asset Management fully exited Gilead Sciences in Q2 2020, selling an estimated $8.8M.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $368M portfolio in Q2 2020.
  • Krensavage Asset Management opened 0 new positions and closed 2 in Q2 2020.
  • Krensavage Asset Management's portfolio value rose 18% quarter-over-quarter to $368M.

Based on Krensavage Asset Management's 13F filing for Q2 2020, filed 17 Aug 2020.